Lyme Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Introduction

GlobalData, the industry analysis specialist, has released a new report, “Lyme Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Lyme disease therapeutics market. The report identifies the key trends shaping and driving the global Lyme disease therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Lyme disease therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated that the Lyme disease therapeutics market was worth $2.2m in 2009. The major reason for this limited market revenue is that there is no approved drug specifically for Lyme disease treatment. Antibiotics such as doxycycline, cefuroxime and amoxicillin are currently prescribed. The patent protection of all these antibiotics expired long ago and many generic versions of the antibiotics are available very cheaply. In 2009, the annual cost of therapy for Lyme disease with antibiotics was $81. Between 2001 and 2009, the Lyme disease therapeutics market grew only at a Compound Annual Growth Rate (CAGR) of 6.1%. The late-stage pipeline for the Lyme disease therapeutics market is very weak and is entirely made up of antibiotics that are currently used as off-label drugs. Therefore, even though these drugs will receive regulatory approval for the Lyme disease therapeutics market, the entry of antibiotics is expected to have a negligible impact on the market in terms of sales value and volume. Overall, between 2009 and 2017, the Lyme disease therapeutics market is expected to grow at a CAGR of only 4.8% to reach $3.2m by 2017.

Scope

The report provides information on the key drivers and challenges in the Lyme disease therapeutics market. Its scope includes:
- Annualized global Lyme disease therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
- The Lyme disease pipeline has antibiotics and potential novel vaccines being studied for the treatment of early as well as late stage Lyme disease. Currently the pipeline comprises third-generation cephalosporin antibiotic, Cephalosporin + Tetracycline combinations, Lyme Borreliosis vaccines, OspA vaccine and OspA + DbpA combination vaccine
- Analysis of the current and future market competition in the global Lyme disease therapeutics market. The key market players operating in this market are Pfizer, Bater International, GlaxoSmithKline and Intercell AG
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the Lyme disease therapeutics market.


Highlights

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global Lyme disease therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Lyme disease therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Lyme disease therapeutics market landscape? – Identify, understand and capitalize.
[Cerrar las informaciones del articulo de mercado]

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Lyme Disease Therapeutics Market : Introduction 6
2.1 Disease Overview 6
2.2 Symptoms 6
2.3 Diagnosis 7
2.4 Treatment 7
2.5 Epidemiology 8
2.6 Prevention 10
2.7 GlobalData Pipeline Report Guidance 11
3 Lyme Disease Therapeutics : Market Characterization 12
3.1 Lyme Disease Therapeutics Market Size 12
3.2 Lyme Disease Therapeutics Market Forecast and CAGR 12
3.3 Drivers and Barriers for the Lyme Disease Therapeutics Market 14
3.3.1 Drivers for the Lyme Disease Therapeutics Market 14
3.3.2 Barriers for the Lyme Disease Therapeutics Market 14
3.4 Opportunity and Unmet Need 15
3.5 Key Takeaway 16
4 Lyme Disease Therapeutics Market : Competitive Assessment 17
4.1 Overview 17
4.2 Strategic Competitor Assessment 17
4.3 Product Profile for the Major Off-label Marketed Products in the Lyme Disease Therapeutics Market 18
4.3.1 Doxycycline 18
4.3.2 Cefuroxime Axetil 19
4.3.3 Amoxicillin 20
4.3.4 Erythromycin (Macrolides) 21
4.3.5 Ceftriaxone 21
4.3.6 Penicillin G 22
4.4 Key Takeaway 24
5 Lyme Disease Therapeutics Market : Pipeline Assessment 25
5.1 Overview 25
5.2 Strategic Pipeline Assessment 25
5.2.1 Technology Trends Analytic Framework 25
5.3 Lyme Disease Therapeutics – Promising Drugs Under Clinical Development 27
5.4 Molecule Profile for Promising Drugs under Clinical Development 27
5.4.1 Lyme Borreliosis Vaccine 27
5.4.2 OspA Chimaeric Vaccine 27
5.4.3 DbpA + OspA 28
5.5 Lyme Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action 28
5.6 Lyme Disease – Pipeline by Clinical Phases of Development 29
5.6.1 Lyme Disease Therapeutics – Phase III Clinical Pipeline 29
5.6.2 Lyme Disease Therapeutics – Phase II Clinical Pipeline 29
5.6.3 Lyme Disease Therapeutics – Pre-clinical Pipeline 29
5.7 Discontinued Drug for Lyme Disease 30
5.7.1 LYMErix 30
5.8 Key Takeaway 30
6 Lyme Disease Therapeutics Market – Implications for Future Market Competition 31
7 Lyme Disease Therapeutics Market : Future Players in the Lyme Disease Therapeutics Market 33
7.1 Introduction 33
7.2 Intercell AG 33
7.2.1 Company Overview 33
7.2.2 Financial Performance 33
7.2.3 Business Description 34
7.2.4 Vaccine Portfolio 34
7.3 Baxter International Inc 35
7.3.1 Company Overview 35
7.3.2 Financial Performance 35
7.3.3 Business Description 35
7.3.4 Vaccine Portfolio 35
8 Lyme Disease Therapeutics Market : Appendix 36
8.1 Market Definitions 36
8.2 Abbreviations 36
8.3 Research Methodology 37
8.3.1 Coverage 38
8.3.2 Secondary Research 38
8.3.3 Forecasting 38
8.3.4 Primary Research 41
8.3.5 Expert Panels 41
8.4 Contact Us 41
8.5 Disclaimer 41
8.6 Sources 42
[Cerrar la tabla de contenidos]

Table 1: Lyme Disease Recommended Antibiotics and Doses, 2010 8
Table 2: Lyme Disease Reported Cases in Top 10 States of America During 1999-2008 10
Table 3: Lyme Disease Therapeutics Market, Global, Revenue ($m), 2001-2009 12
Table 4: Lyme Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 13
Table 5: Clinical Effectiveness of Ceftin Tablets Compared to Doxycycline, 2010 20
Table 6: Major Off-label Marketed Products Comparison in Lyme Disease Therapeutics Market, 2010 23
Table 7: Lyme Disease Therapeutics – Most Promising Drugs Under Clinical Development, 2010 27
Table 8: Lyme Disease Therapeutics – Phase III Clinical Pipeline, 2010 29
Table 9: Lyme Disease Therapeutics – Phase II Clinical Pipeline, 2010 29
Table 10: Lyme Disease Therapeutics – Pre-clinical Pipeline, 2010 29
Table 11: Intercell AG – Marketed Vaccines, 2010 34
Table 12: Intercell AG – Pipeline Products, 2010 34
Table 13: Baxter Vaccine– Pipeline Products, 2010 35
Figure 1: Lyme Disease Reported Cases in Top 10 States of America, 2010 9
Figure 2: Lyme Disease Therapeutics, Global, Market Revenue ($m), 2001–2009 12
Figure 3: Lyme Disease Therapeutics Market, Global, Revenue Forecast ($m), 2009–2017 13
Figure 4: Opportunity and Unmet Need in the Lyme Disease Therapeutics Market 15
Figure 5: Strategic Competitor Assessment of the Major Off-label Products for Lyme Disease, 2010 17
Figure 6: Technology Trends Analytic Framework of the Lyme Disease Pipeline, 2010 26
Figure 7: Technology Trends Analytic Framework of the Lyme Disease Pipeline - Description, 2010 26
Figure 8: Lyme Disease Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 28
Figure 9: Lyme Disease Pipeline by Phase of Clinical Development, 2010 29
Figure 10: Implications for Future Market Competition in the Lyme Disease Therapeutics Market, 2010 31
Figure 11: Lyme Disease Therapeutics Market – Clinical Pipeline by Company, 2010 33
Figure 12: GlobalData Market Forecasting Model 40
[Ocultar lista de tablas / figuras]